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Abstract 
 
We tested the hypothesis that selected prothrombotic biomarkers might be associated with 
early spontaneous coronary recanalization in patients with ST-segment elevation acute 
myocardial infarction (STEMI).  
 We prospectively enrolled 123  patients with STEMI including 53 patients with spontaneous 
coronary recanalization (Cases) and 70 patients with persistent occlusion (Controls) at the 
time of emergent coronary angiography and before angioplasty. All had received aspirin and 
heparin. Blood samples  were collected immediately before angioplasty to measure soluble P-
selectin, circulating microparticles originating from platelets (PMPs), granulocytes (GMPs), 
endothelial cells (EMPs); tissue factor-associated MP (TF-MP); soluble platelet glycoprotein 
V (sGPV) and prothrombin F1+2; tissue plasminogen activator (tPA), plasminogen activator 
inhibitor (PAI-1) and plasmin-antiplasmin (PAP). A sub-group of 70 patients (35 cases, 35 
controls) was available for flow cytometry analysis of platelet P-selectin and activated GPIIb-
IIIa. Baseline clinical characteristics did not differ between groups except for more frequent 
hypertension and dyslipidemia in Controls. Platelet activation markers and PMP did not differ 
between the two groups. Controls had higher numbers of EMPs and GMPs compared to 
Cases, but the difference was no longer significant when corrected for risks factors. Controls 
differed from Cases by higher plasma levels of sGPV [64 (47-84) ng/ml vs 53 (44-63) ng/ml] 
and PAP [114(65-225) ng/ml vs 88 (51-147) ng/ml]. The difference persisted after adjustment 
for risks factors (p=0.031 and 0.037, respectively). Persistent occlusion of the infarct related 
artery is associated with some markers related to higher thrombin (sGPV) and plasmin (PAP) 
production but is not  associated with markers of platelet activation .  
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KEYWORDS: myocardial infarction ,  thrombin , soluble Glycoprotein V, endothelial 
injury,  plasmin-antiplasmin, . 
 
Introduction 
Acute myocardial infarction (AMI) results from the disruption of unstable 
atheromatous plaques exposing thrombogenic material to blood flow and initiating the 
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formation of an occluding arterial thrombus. Platelet activation is triggered by contact with 
collagen in the extracellular matrix of the plaque, while tissue factor produced by 
macrophages and smooth muscle cells induces thrombin formation (1). Thrombin amplifies 
the activation of platelets and converts fibrinogen to fibrin, yielding the characteristic arterial 
thrombus formed of platelets entrapped in fibrin. Furthermore, microparticles (MPs) resulting 
from cell activation/apoptosis within the atheromatous plaques (2) contribute to plaque 
thrombogenicity and may disseminate blood-borne tissue factor activity and procoagulant 
phospholipids upon plaque rupture (3). Natural fibrinolytic mechanisms (plasminogen 
activators tPA and uPA) contribute to the dissolution of arterial thrombi. However, high 
levels of the plasminogen activator inhibitor PAI-1 (associated with several genetic or 
environmental factors) limit the efficacy of spontaneous fibrinolysis and this factor has been 
recognized to contribute to cardiovascular risk (4). 
Primary percutaneous coronary intervention (PCI) is now  established as the reference 
therapy for the management of ST segment elevation AMI (5). Before PCI, approximately 15-
18 % of patients present with angiographically proven spontaneous patency of the infarct 
artery. These patients have less myocardial damage and a better outcome than patients with 
occluded arteries (6, 7). In the present prospective study, we sought to determine whether 
patients with spontaneous recanalization of the infarct related artery differ from patients with 
persistent occlusion at the time of initial angiography, before PCI, in terms of selected 
biomarkers of cell stimulation, coagulation and/or fibrinolysis activation. This analysis may 
provide insight into the optimal pathways for improving current pharmacologic therapies 
designed to recanalize infarct arteries. 
METHODS 
Study design 
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We undertook a prospective case-control study comparing patients who presented 
with patent artery at the time of emergency coronary angiography (cases) and patients with 
occluded artery (controls). 
 
Study patients: 
Inclusion and exclusion criteria 
 Patients were eligible for inclusion if they were between 18-80 year old, with 
symptoms of acute coronary syndrome  within the past 12 hours, ST-segment elevation of 
greater than 1 mm on their electrocardiogram and creatine kinase twice the upper limit of 
normal. Patients were excluded if they presented with life-threatening arrythmia, 
hemodynamic instability or shock or if they had received within 30 days (including the 
present episode), thrombolytics, GpIIb/IIIa receptor blockers, ticlopidine or clopidogrel, or 
had undergone angioplasty in the preceding 6 months. From October 2000 to December 2003, 
we enrolled a total of 123 patients  who were triaged to primary percutaneous transluminal 
coronary angioplasty (PTCA). Patients were transported promptly to the catheterization 
laboratory and underwent immediate coronary angiography. Flow was assessed at the first 
contrast injection via the guiding catheter before any wire crossing. All patients had received 
sublingual or IV nitroglycerin.  
Definition of Cases and Controls 
Coronary flow  was evaluated  quantitatively according to the Thrombolysis In 
Myocardial Infarction (TIMI) grading system (8). Fifty three patients had a grade TIMI 2-3 
and constituted the cases whereas 70 patients had a grade TIMI 0-1 and constituted the 
controls. All the patients had received 250 to 500 mg aspirin and 5000 UI of unfractionated 
heparin before blood collection and angiography. The vast majority received abciximab just 
before angiography but after blood collection was performed (Table I) The protocol was 
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approved by the local Ethics Committee. Written informed consent was obtained from all 
patients. 
Healthy volunteers 
Normal reference values for each prothrombotic markers was determined in 24 healthy 
volunteers 24-65 year old (median 45), 12 females and 12 males, free of known cardio-
vascular risks factors. Reference values for plasmin-antiplasmin complexes were determined 
by one of the co-authors (EAC) in a large cohort including 125 healthy volunteers 21-80 year 
old ( median 52) comprising 56 females and 69 males. All these individuals have given their 
informed consent. 
 
Blood sampling and processing: 
Venous peripheral blood was collected from all patients on admission, just before 
angiography and treatment with abciximab. Blood was drawn in evacuated tubes 
(Vacutainer®, Becton-Dickinson) containing 0.129 M trisodium citrate (1 vol / 9 vol blood), 
for all assays but plasma soluble GPV (sGPV) measurement  (tubes contained CTAD:  
0.109M sodium citrate, citric acid, theophylline, adenosine, and dipyridamole) and 
fibrinolysis parameters analysis (tubes contained CTAD, 100 nM PPACK and 10 UI/ml 
aprotinin). Blood was centrifuged within one hour either at 2,500 g for 20 minutes at 14°C for 
plasma proteins assays or at 1,500 g for 20 minutes at 20°C for microparticles (MPs) 
isolation. Plasma was kept frozen at – 80°C until analysis.  
 
Whole blood platelet activation markers:
Platelet surface P-Selectin (CD62P, Immunotech, Le Pont-de-Chaix, France) and 
activated GPIIbIIIa (PAC-1, IgM, Beckton-Dickinson) were analyzed in whole blood by 
flow cytometry within two hours of blood collection. Preliminary experiments demonstrated 
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that these parameters were stable up to two hours after blood collection which limited the 
flow cytometry study to a sub-group of 35  TIMI 2-3 patients and 35  TIMI 0-1 patients 
corresponding to patients included when flow cytometry could be rapidly performed. Whole 
blood samples (5Ql) diluted 1:10 in PBS were incubated with saturating concentrations of 
fluorescein-conjugated antibodies CD62P, PAC-1 or isotype-matched controls for 30 minutes 
in the dark and after addition of 1 ml PBS, immediately analyzed by flow cytometry. 
Percentage of positive platelets were determined as compared to isotype-matched controls. 
Normal values were less than 2 % for each marker. 
 
Microparticles (MPs) isolation and characterization:
Microparticles  were isolated according to Nieuwland et al (9) and analyzed in a 
Coulter Epics XL with Expo 32 software (Beckman Coulter). In brief, MPs were extracted 
from plasma within 2 months of storage at –80°C by centrifugation at 18 000g for 20 min at 
RT, the pellet being washed once in working buffer (WB:10 mM Hepes pH 7.35, 136 mM, 5 
mM KCl, 2 mM MgCl2) containing either 5 mM EDTA (first washing) or no EDTA (for the 
second washing). The pellet was finally resuspended in WB and directly analyzed by flow 
cytometry. Extracted MPs (5 Ql) were incubated for 30 min in the dark with 45 Ql WB 
containing 2 mM CaCl2 and 5 Ql fluorochrome-conjugated probes, consisting of  fluorescein-
isothiocyanate (FITC)-annexin V (Immunotech ) and phycoerythrin(PE)-conjugated specific 
monoclonal antibodies (MoAbs). MoAbs included  anti-CD15 (Lewisx, clone 80175, IgM), 
anti-CD41(GPIIb, clone P2, IgG1), anti-CD106 (VCAM1, clone 5110 C9, IgG1) or isotype 
controls IgG1 (MOPC21) or IgM (G155-228) (from Immunotech, and PharMingen, San José, 
CA). Normal values [median(IQR)] of annexinV-positive MPs (total MPs) in 24 normal 
healthy adult volunteers were 365 (281-596) /Ql, originating from platelets (PMPs: 87%), 
granulocytes (GMPs: 5%) and  endothelial cells (EMPs: 1.5%). 
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Microparticle-linked tissue factor activity.  
Tissue factor (TF) activity associated to MPs (TF-MP) was determined through the 
ability of MPs to promote the activation of F X  by F VIIa, as described by Key et al (10). In 
brief, the MPs suspension was mixed with 1 nM recombinant  FVIIa (gift from Novo 
Nordisk, Måløv, Denmark) and 250 nM human FX (Enzyme Research Laboratory, South 
Bend, IN, USA). After 3 minutes incubation at 37°C, normal plasma containing 12.5 QM
phospholipids (20% phosphatidyl-serine / 80% phosphatidyl-choline) was added and the 
clotting time was recorded after addition of 5 mM CaCl2. A standard curve was constructed 
using relipidated human recombinant TF (American Diagnostica, Greenwich, CT, USA), and 
results were expressed as pg/ml of TF-MP. The specificity of the assay was ascertained by the 
use of inactivated FVIIa (VIIai, Novo Nordisk,) or a blocking anti-TF MoAb (American 
Diagnostica) which both completely abolished  FXa generation in presence of TF. Normal 
values [median (IQR)] established in 20 healthy adult volunteers were 35.5 (29-50) pg/ml. 
 
Soluble P-selectin (sPselectin), soluble GPV (sGPV) and Prothrombin fragment 
1+2 (F 1+2)
Plasma levels of sPselectin, sGPV and F 1+2 were measured using enzyme-linked 
immunosorbent assays (ELISA) (sPselectin, R&D systems Europe, Lille; sGPV, Serbio, 
Gennevilliers, France and Enzygnost F 1+2, Dade-Behring, Marburg, Germany, respectively). 
Normal values for plasma sGPV [median (IQR)]  were 25.1 (14.8 – 39.9) ng/ml, very similar 
to the  values recently reported in 300 healthy blood donors (11). Normal values indicated by 
the manufacturer for F 1+2 (median and 5th to 95th percentile) was 115 (69-229) pmol/L. 
 
Biomarkers of  fibrinolysis. 
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The mass concentrations of tPA and PAI-1 were measured by ELISA using 
commercially available reagents from Serbio, France. Plasmin-2 antiplasmin complexes 
(PAP) were measured using a local ELISA, using specific antibodies as described by Montes 
et al (12). Normal values [median (IQR)] established from 125 healthy controls were 24.8 
(7.3-35.4) ng/ml. 
 
Statistical analysis   
Continuous variables were expressed as median and interquartile range (IQR), and 
distributions of qualitative variables were presented with number of patients and percentages. 
All STEMI patients were included in the analyses (except for platelet P-selectin and activated 
GpIIb-IIIa which were available in 35 cases and 35 controls). We first tested the relation 
between the baseline characteristics and the status of the patients: case (i.e spontaneous 
coronary recanalization) or control  (persistent occlusion) in an univariate analysis with the 
Mann-Whitney test (continuous variables), Chi square test or Fischer exact test as appropriate 
(qualitative variable).  
When biological markers associated with the case versus control status with a p value 
 0.20 in the univariate analysis, they were included simultaneously  in a multivariate logistic 
regression model adjusted on the known coronary risk factors (sex, age, smoking status, 
hypertension, diabetes mellitus, dyslidemia, anterior MI, delay of revascularization) to 
evaluate their specific effects. The presence of an interaction between selected biological 
markers and each of the clinical variables,  was also tested in the logistic regression model. 
All analyses were performed with SPSS statistical software version 11.0 (SPSS Inc., Illinois, 
Chicago).  
A Spearman correlation was computed between biological variables and TF activity. 
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RESULTS 
Patients characteristics 
Among the 123 patients enrolled in this prospective study, 53 achieved TIMI 2 to 3 
flow  (15 TIMI 2 and 38 TIMI 3 flow) and 70 had TIMI 0-1 flow on baseline (pre-
intervention) coronary angiography. Patients with TIMI grade 2 patency did not differ from 
patients with TIMI 3 flow in terms of biomarkers and  the data were therefore pooled together 
(TIMI 2-3) for comparison with TIMI 0-1 patients. Killip class I was not different between 
groups (88.7% W 91.4% respectively in cases W controls), as well as Killip class II (11.3% W
8.6% in cases W controls). Systolic (SBP) and Diastolic Blood pressure (DBP) did not differ 
either between groups [125(113-152) mmHg, median(IQR) W 128(112-145)] and [76(69-90) 
mmHg W 75(68-90)] in cases W controls respectively. The baseline characteristics are listed in 
Table 1 and were similar between groups, with the exception of dyslipidemia and 
hypertension, which were less frequent in patients with TIMI 2-3 flow (spontaneous 
recanalization) than in TIMI 0-1 patients (occluded artery). The time delay from symptoms 
onset and recanalization (spontaneous or instrumental) did not differ between the two groups. 
 
Cell activation markers.
As previously observed by others (13), platelet surface expression of P-selectin and 
activated GPIIb/IIIa  was increased in patients compared to healthy controls. However, no 
significant difference was observed between TIMI 0-1 and 2-3 patients  (Table 2). Soluble P-
selectin was not different between groups, 42 (31.9-54.2) ng/ml , median (IQR) and 40 (33.3-
49.2) ng/ml  in TIMI 0-1 and TIMI 2-3 respectively. Likewise, the platelet-derived MPs ( 
PMPs) were not different in the two groups of patients (Table 3). In contrast, the numbers of  
both GMPs and EMPs were significantly lower in patients with patent infarct arteries 
compared to patients with occluded vessels (Table 3, p=0.021 and 0.002, respectively). The 
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difference disappeared after adjustment for baseline risk factors. EMPs in TIMI 2-3 patients 
correlated with SBP (r=0.307, p=0.038). 
 
Tissue factor.  
 Tissue factor activity  associated to MPs (TF-MP) did not differ from normal values 
in TIMI 2-3 patients,  but was significantly increased in TIMI 0-1 patients  compared to 
healthy controls (p=0.0012). However, although levels of TF-MP tended to be lower  in 
patients with patent vs occluded vessels (Table 3), the difference did not reach significance. 
TF-MP activity correlated with PMPs numbers ( r=0.287, p = 0.0012). 
 
Prothrombin F1+2 and sGPV 
Plasma levels of prothrombin F1+2 were not significantly different between the two 
patients’ groups [136 (60-211) pM/l and 151 (57-246) pM/l, median (IQR), for TIMI 2-3 and 
TIMI 0-1 patients, respectively].  We observed a negative correlation between F1+2 levels and 
anti-Xa activity (r= -0.254, p=0.0052). 
As previously reported by others (14, 15), increased plasma levels  of sGPV  were 
observed  in our patients, reflecting the important role of platelet activation by thrombin in the 
acute phase of myocardial infarction. Moreover, sGPV was significantly (p= 0.031) lower in 
TIMI 2-3 patients [53 (44-63) ng/ml] compared to TIMI 0-1 patients [64 (47-84) ng/ml] (fig. 
1) . The difference persisted after adjustment for risk factors (p=0.002). A weak correlation 
was observed between sGPV and  TF-MP (r=0.293, p=0.031).  
 
Biomarkers of fibrinolysis. 
Plasma levels of tPA antigen  were significantly ( p=0.011)  lower in TIMI 2-3 [7 (6-
11) ng/ml] than in TIMI 0-1 patients  [10 (7-13) ng/ml]. The difference disappeared after 
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adjustment for cardiovascular risks factors (p=0.303). Plasma levels of PAI-1 were similar in 
TIMI 2-3 patients [22 (11-44) ng/ml ] and TIMI 0-1 patients [22 (12-45) ng/ml]. Plasma 
levels of PAP complexes were increased in the two groups of patients (fig.2), but significantly 
lower  in TIMI 2-3 patients [88 (51-147) ng/ml] compared to TIMI 0-1 patients [114 (65-225) 
ng/ml] (p=0.041). The difference persisted after adjustment for risk factors (p=0.037) (fig.2) . 
 
DISCUSSION 
Our prospective study aimed to use spontaneous recanalization of the infarct vessel (in 
patients who received standardized antithrombotic therapy with aspirin and unfractionated 
heparin) as a paradigm for antithrombotic therapy in STEMI. Investigating differences in 
circulating markers of platelet activation, tissue factor expression, thrombin generation and 
fibrinolysis may be valuable to guide selection of additional antithrombotic therapy. The main 
result of the present analysis is that there are little differences between patients with occluded 
versus patent vessels in STEMI with respect to markers of platelet activation, except sGPV. In 
contrast, significant differences were observed in terms of leukocytes and endothelial cells 
activation. However, these differences disappear after adjustment on risk factors, indicating 
that the latter are causal. In addition, PAP and tPA lev ls were lower, paradoxically, in 
patients with patent versus those with occluded vessels. 
Platelet-dependent thrombosis is known to play a critical role in patency and 
recanalization of the infarct artery in acute myocardial infarction. Yet our study failed to show 
differences in terms of platelet activation (platelet surface P-selectin and activated GPIIb-IIIa, 
or PMPs) between patients with patent versus occluded vessels. In contrast, Yip et al (13) 
have recently showed  that platelet surface P-selectin was independently associated with the 
extent of myocardial necrosis in patients with AMI. We cannot exclude that antithrombotic 
treatment (aspirin + heparin) already introduced at the time of blood sampling in the present 
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study has masked potential differences in the extent of platelet activation between the two 
groups of patients.  Previous observations have shown that unfractionated heparin decreases 
levels of circulating P-selectin and platelet activation in vivo (16). Aspirin influences P-
selectin expression on platelets and inhibits baseline reactivity in patients with AMI (17, 18). 
However, it is questionable if this treatment could  have influenced PMPs numbers .  
As previously described by others (2, 15, 19), acute myocardial infarction was 
associated with an increase shedding of MPs originating from endothelial cells (EMP). 
Interestingly, patients with early spontaneous coronary recanalization exhibited significantly 
lower numbers of circulating EMPs than those with persistent occlusion. EMPs are also 
associated with multiple concommittent risk factors, in particular with hypertension (20, 21). 
In the present work and consistent with a previous study (21), we found a correlation between 
EMPs and SBP, but only in cases. This apparent paradox might indicate that the 
mechanism(s) involved in EMPs generation in patients with persistent occlusion would be 
different and probably more complex than in patients with early spontaneous coronary 
recanalization. We also observed an increase in GMPs in our patients, which was significantly  
lower in TIMI 2-3 versus TIMI 0-1 patients. The present finding extend previous observations 
demonstrating the involvement of leukocyte-derived  MPs in the thrombus growth (22) and 
plaque burden (23). The difference in EMPs and GMPs levels was no more significant after 
adjustment for baseline risk factors, indicating that hypertension and dyslipidemia, which 
were less prevalent in TIMI 2-3 patients, contribute to the differences in MPs shedding from 
endothelial cells and leukocytes. EMPs and GMPs constitute reliable hallmarks of vascular 
injury (24) and inflammatory response, which suggests that an inverse relationship between 
the severity of vascular and inflammatory cells damage and early spontaneous recanalization 
is highly probable. Alternatively, MPs can act as diffusible messengers, transporting bioactive 
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agents (25, 26),  and high levels of EMPs and GMPs could contribute to the persistence of the 
coronary occlusion.  
Tissue factor is the initial activator of the blood coagulation pathway that leads to 
thrombin generation and culminates in the fibrin clot formation. Elevated intra-vascular TF, 
blood-borne or shedded from ruptured plaque, has been reported in MI (27, 28) and MPs 
contribute at least in part to this activity (2). The correlation between TF activity and PMPs, 
although weak, may suggest that TF-MP is in part supported by PMPs, probably resulting 
from multiple fusions and exchanges between leukocyte, endothelial and platelet plasma or 
MP membranes (29) or resulting from platelet TF synthesis upon activation (30). We found a 
trend for lower levels of TF-MP in patients with early spontaneous recanalization compared 
to patients with persistent occlusion. It is unclear whether this merely reflects lack of power of 
our small study or a true lack of difference. In addition, TF activity on MPs is modulated by 
its inhibitor TFPI (31), which is susceptible to proteolysis thereby limiting its inhibitory 
activity (32, 33).  
A reduced generation of thrombin was also associated with spontaneous coronary 
reperfusion, as indicated by a lower level of sGPV in TIMI 2-3 patients. However, the causal 
role of TF-MP in sGPV shedding could not be directly established in the present study since 
the  two markers were  weakly correlated.  
Platelet GPV is directly cleaved by thrombin during platelet activation and sGPV is an 
indirect but exquisitely sensitive marker of thrombin presence (34). This study indicates that 
sGPV represents a more sensitive marker of thrombin-induced platelet activation than PMPs. 
The increased levels of sGPV in patients with occluded infarct arteries thus suggest increased 
presence of thrombin compared to patients with patent arteries. However, in contrast to sGPV, 
prothrombin F 1+2 levels were similar in the two groups of patients, all of which were treated 
with unfractionated heparin. The influence of this treatment is highly suggested by the 
Page 14 of 28Thrombosis and Haemostasis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
H
AL author m
anuscript    inserm
-00160732, version 1
For Peer Review
15
correlation between F 1+2 levels and anti-Xa activity as already reported (35). We hypothesize 
that sGPV, which has a longer half-life than F 1+2 , represents a better marker of thrombin 
generation in patients receiving heparin (34, 36). 
In addition to thrombin, TNF-alpha converting enzyme (TACE or ADAM17), a 
metalloproteinase that is present in platelets,  is capable of cleaving GPV (37) upon platelet 
activation. The ELISA used for the sGPV assay does not discriminate between both fragments 
released.  Consequently, we cannot eliminate the impact of this mechanism in the shedding 
process, although its contribution would be improbable since we did not evidence differences 
in platelet activation between the two groups of patients. 
Baseline levels of the fibrinolytic components tPA and PAI-1 are recognized 
biomarkers linked to the risk of major cardiovascular events (38). Lower levels of tPA may 
appear paradoxical in recanalized patients. Since the tPA assay measures, to a large extent, 
inactive tPA/PAI complexes, increased tPA antigen levels may be viewed as a correlate of 
increased PAI-1 activity (39). Plasma levels of tPA antigen are relatively constant over time 
while PAI-1 antigen levels fluctuate markedly (39), perhaps explaining why the former is a 
more sensitive marker than the latter. We hypothesize that lower tPA levels in recanalized 
patients may be related to less endothelial injury mainly modulated by baseline risk factors. 
The lower level of PAP observed in TIMI 2-3 patients suggests that less plasmin is generated 
in recanalized patients at the time of blood sampling, which may be the direct consequence of 
low levels of fibrin-bound tPA able to transform plasminogen into plasmin. Alternatively, the 
higher levels of PAP in TIMI 0-1 patients could result from plasminogen activation by  uPA 
as a consequence of the greater granulocyte activation (40, 41) observed in this group of 
patients. 
 Our results suggest that there may be differences in the arterial lesions and/or the 
hemostatic system between patients with STEMI: less endothelial injury and granulocyte 
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stimulation, lower levels of thrombin and plasmin generation appear to correlate with a 
greater chance of early recanalization of the infarct vessel in patients receiving heparin, and 
antiplatelet therapy.  In addition, our results also show the impact of classical risk factors on 
persistent coronary thrombosis. Indeed, in the present study, hypertension and dyslipidemia 
appeared to play a critical role in differences in markers of cell activation, in accordance with 
previous observations (42, 21). Our results indicate that antithrombotic treatment with 
molecules active on thrombin generation or activity such as the pentasaccharide (43) or 
bivalirudin (44, 45) might favor spontaneous recanalization and deserve to be tested.  
Study Limitations  
A potential limit of our study is the selection of cases and controls towards inclusion 
of the most stable patients. The small size of the study could have also underpowered 
differences between groups. 
Flow cytometry on platelets was performed only in 35 patients in each group which 
corresponded to patients included during the day-time. It is possible that this selection has 
introduced a bias in platelet activation markers (46). 
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Legends to Figures and Tables 
 
Figure 1.  
Soluble GPV (sGPV)  in 70 controls (TIMI 0-1, grey bars) and 53 cases (TIMI 2-3, clear 
bars). P value was calculated after adjustment on baseline cardio-vascular risk factors. In 
these plots, lines within boxes represent median values, the lower and upper lines of the boxes 
represent the 25th and 75th percentiles, respectively, and the lower and upper bars outside the 
boxes represent the 10th and 90th percentiles, respectively.  
 
Figure 2.  
Plasmin-antiplasmin (PAP) complexes in 70 controls (TIMI 0-1, grey bars) and 53 cases 
(TIMI 2-3, clear bars) patients. P value was calculated after adjustment on baseline cardio-
vascular risk factors. Plots are outlined as in figure 1.  
 
Table 1 
Qualitative variables are expressed as number (observed number/total number) and (%), and 
quantitative variables are expressed with median and range (minimum-maximum). 
 
Table 2 
Platelet P-selectin and activated GpIIb-IIIa (PAC-1) expression as measured by flow 
cytometry in 35 controls (TIMI 0-1 flow) and 35 cases ( TIMI 2-3 flow). Data are expressed 
as per cent positive platelets as compared to isotype controls. 
 
Table 3. 
Microparticles (MPs) values are expressed as number per Ql, median (interquartile range, 
IQR); PMPs: platelet derived MPs; GMPs: granulocyte-derived MPs; EMPs: endothelial 
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derived MPs;  TF-MP: Tissue factor associated with microparticles. TF-MP activity is 
expressed as pg/ml, median (IQR). 
P value according to Mann-Whitney U-test. P value of logistic regression  after correction 
for risk factors – age, smoking, hypertension, dyslipidemia, diabetes mellitus, anterior 
location of MI, delay between onset of pain and recanalization . 
 
Table 1. Patients Baseline Characteristics 
 
Variables TIMI 2/3 patients 
(n=53) 
TIMI 0/1 patients 
(n=70) 
p value 
Women 3/53 (5.8) 11/70 (15.7) 0.088 
Age (years), median (range) 53 (34-80) 57 (29-80) 0.385 
Age > 70 years 8/53 (15.1) 11/70 (15.7) 0.611 
Hypertension  12/53 (22.6) 30/69 (43.5) 0.016 
Prior or current smoking 46/52 (88.5) 54/69 (78.2) 0.321 
Dyslipidemia  18/53 (34.0) 36/69 (52.2) 0.045 
Diabetes mellitus  7/53 (13.2) 8/70 (11.4) 0.765 
Delay from symptoms onset to 
recanalization (hours), median (range) 
3.0 (1.3-10.9) 3.5 (0.4-9.4) 0.377 
Delay from symptoms onset to 
recanalization >2 hours  
47/53 (88.7) 52/63 (82.5) 0.352 
Anterior myocardial infarction  22/53 (41.5) 23/70 (32.8) 0.324 
Abciximab  before coronarography 43/53 (81.1) 62/70 (88.6) 0.248 
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Table 2. Platelet P-selectin and PAC-1 expression by flow cytometry. Per cent positive 
platelets, median(IQR) 
 
TIMI 0/1 
N=35 
TIMI 2/3 
N=35 
p
P-selectin  
 
3.6 (2-6.1) 5.2 (1.6-10.3) 0.173 
 
PAC-1  
 
12 (6-21) 13.2 (4-33) 0.411 
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Table 3 . Microparticles quantification, cellular origin and  associated-TF activity in 
patients with AMI according to their flow grade. 
 
Microparticles TIMI 0/1  
N=70 
TIMI 2/3  
N=53 
P p*
Origin     
Total  MPs  507 (186-738) 312 (152-751) 0.331 1.000 
PMPs  386 (112-677) 251 (104-459) 0.126 1.000 
GMPs  38 (13-112) 27 (10-62) 0.021 0.995 
EMPs  14 (8-26) 11 (4-15) 0.002 0.991 
Activity     
TF-MP pg/ml 72 (31-151) 40 (22-101) 0.09 0.996 
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